Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhen R, Weinberg AD, Spencer CN, Ng D, He XY, Albrengues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T. Hirschhorn D, et al. Among authors: holland a. Cell. 2023 Mar 30;186(7):1432-1447.e17. doi: 10.1016/j.cell.2023.03.007. Cell. 2023. PMID: 37001503 Free PMC article.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. Chow A, et al. Among authors: holland a. Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001. Epub 2022 Dec 26. Immunity. 2023. PMID: 36574773 Free PMC article.
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.
Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho YJ, Campesato LF, Mangarin L, Fak J, Suek N, Holland A, Liu C, Abu-Akeel M, Bykov Y, Zhong H, Fitzgerald K, Budhu S, Chow A, Zappasodi R, Panageas KS, de Henau O, Ruscetti M, Lowe SW, Merghoub T, Wolchok JD. Ghosh A, et al. Among authors: holland a. J Clin Invest. 2022 Sep 15;132(18):e148141. doi: 10.1172/JCI148141. J Clin Invest. 2022. PMID: 36106631 Free PMC article.
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. Sahu A, et al. Among authors: holland a. Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. Nat Commun. 2022. PMID: 36085288 Free PMC article.
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.
Kraehenbuehl L, Holland A, Armstrong E, O'Shea S, Mangarin L, Chekalil S, Johnston A, Bomalaski JS, Erinjeri JP, Barker CA, Francis JH, Wolchok JD, Merghoub T, Shoushtari AN. Kraehenbuehl L, et al. Among authors: holland a. Cancers (Basel). 2022 May 26;14(11):2638. doi: 10.3390/cancers14112638. Cancers (Basel). 2022. PMID: 35681616 Free PMC article.
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Davar D, et al. Among authors: holland a. Clin Cancer Res. 2022 Sep 15;28(18):3990-4002. doi: 10.1158/1078-0432.CCR-22-0339. Clin Cancer Res. 2022. PMID: 35499569 Free PMC article.
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Segal NH, Cercek A, Ku G, Wu AJ, Rimner A, Khalil DN, Reidy-Lagunes D, Cuaron J, Yang TJ, Weiser MR, Romesser PB, Stadler ZK, Varghese AM, Ganesh K, Yaeger R, Connell LC, Faleck D, Abou-Alfa GK, Mcauliffe KC, Vaiskauskas P, Solter ML, Ogle M, Adamow MJ, Holland A, Vedantam P, Wong P, Merghoub T, Vakiani E, Hollmann TJ, Juluru K, Chou JF, Capanu M, Erinjeri J, Solomon S, Yamada Y, Kemeny N, Crane CH, Saltz LB. Segal NH, et al. Among authors: holland a. Clin Cancer Res. 2021 Apr 15;27(8):2200-2208. doi: 10.1158/1078-0432.CCR-20-2474. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504552 Free PMC article. Clinical Trial.
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA. Zamarin D, et al. Among authors: holland a. J Immunother Cancer. 2020 Jun;8(1):e000829. doi: 10.1136/jitc-2020-000829. J Immunother Cancer. 2020. PMID: 32503949 Free PMC article. Clinical Trial.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: holland a. Nat Med. 2024 Apr 23. doi: 10.1038/s41591-024-02942-7. Online ahead of print. Nat Med. 2024. PMID: 38653864